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Abstract Magnetic resonance imaging (MRI) is the
imaging modality of choice by which to monitor patient
gliomas and treatment effects, and has been applied to
murine models of glioma. However, a major obstacle to the
development of effective glioma therapeutics has been that
widely used animal models of glioma have not accurately
recapitulated the morphological heterogeneity and invasive
nature of this very lethal human cancer. This deﬁciency is
being alleviated somewhat as more representative models
are being developed, but there is still a clear need for rel-
evant yet practical models that are well-characterized in
terms of their MRI features. Hence we sought to chronicle
the MRI proﬁle of a recently developed, comparatively
straightforward human tumor stem cell (hTSC) derived
glioma model in mice using conventional MRI methods.
This model reproduces the salient features of gliomas in
humans, including ﬂorid neoangiogenesis and aggressive
invasion of normal brain. Accordingly, the variable, inva-
sive morphology of hTSC gliomas visualized on MRI
duplicated that seen in patients, and it differed considerably
from the widely used U87 glioma model that does not
invade normal brain. After several weeks of tumor growth
the hTSC model exhibited an MRI contrast enhancing
phenotype having variable intensity and an irregular shape,
which mimicked the heterogeneous appearance observed
with human glioma patients. The MRI ﬁndings reported
here support the use of the hTSC glioma xenograft model
combined with MRI, as a test platform for assessing can-
didate therapeutics for glioma, and for developing novel
MR methods.
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Introduction
A major obstacle to the development of effective glioma
therapeutics and imaging agents is that until very recently,
murine models of glioma have not accurately recapitulated
the heterogeneous and highly invasive nature of this lethal
form of brain cancer [1–3]. Even though these models have
limitations, they are widely used, and in longitudinal
studies the tumors are usually tracked with quantitative
ﬂuorescence/bioluminescence imaging [4, 5]. Optical
methods do not capture tumor morphology, but magnetic
resonance imaging (MRI), which has been applied to
xenograft models, is able to acquire detailed images of
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combination of a truly representative glioma model, and
the imaging detail provided by MRI, to generate more
relevant assessments of candidate glioma therapeutics [1].
Accordingly we sought to characterize the MRI features of
a comparatively new murine model of glioma [8]. This
model is an orthotopic xenograft using human glioma stem
cells (hTSCs) that has been recently described- it closely
reproduces the biology of glioma in humans, and it is
straightforward to implement [8]. Our goal was to analyze
conventional MRIs acquired longitudinally over several
weeks to fully chronicle the behavior of the hTSC model,
and thus create a glioma model/MRI—based test platform.
A rapidly evolving focus in glioma research is to iden-
tify agents that can suppress the invasive character of the
disease [9]. Widely used glioma models such as the U87,
U251 and U373 human glioma cell lines implanted in the
frontal cortex of mice, while very useful for some types of
studies, grow mainly by enlargement of the tumor mass,
and do not exhibit inﬁltrative and invasive growth [1, 10–
13]. While the recognized need for new glioma models has
elicited the creation of genetic models which effectively
recapitulate the features of patient tumors, these models
create tumors in a variable time scale and only in a small
proportion of the animals and are thus not entirely practical
[1, 6, 7, 14]. Another strategy for establishing in vivo test
platforms is to transplant murine glioma neurospheres into
the brains of immunocompromised (SCID) mice [15]. A
recent variant of this approach utilizes human tumor stem
cells (hTSC) implanted into the mouse brain, and has been
shown to quite closely recapitulate the genotypic and
phenotypic features of the original human tumor [13].
There are several reasons why such models should be
characterized in terms of their MRI features. First, MRI is
the modality of choice to routinely monitor tumor progress
in glioma patients, so in mice the tumor response to a
speciﬁc therapy can most directly be related to what might
be observed in patients by using the same imaging
modality [6]. In addition, MRI allows imaging of unlabeled
cells, while optical methods require the tumor cells to
stably express a ﬂuorophore protein which might bias
tumor cell behavior [16]. Finally, MRI is a non-invasive
and accurate method by which tumor growth and volume
can be determined in live mice.
Our proposed test platform is intended to facilitate MR
brain imaging and contrast agent development. Although
robust contrast enhancement is the clinical MRI marker of
high tumor grade, up to 45% of non-enhancing lesions
prove to have high grade histology at biopsy, and a small
but signiﬁcant number (4%) of gliomas lack contrast
enhancement [17–23]. Equally signiﬁcantly, the correlation
between histopathologic tumor grade and time to progres-
sion and survival is imperfect [21–23]. A large number of
advanced techniques are under study in this context.
Improvement in the reproducibility and sensitivity of rou-
tine contrast enhanced imaging might be facilitated using a
cost-effective, practical, and relevant xenograft model.
In view of the foregoing, we sought to determine if the
mouse hTSC model displayed the salient MRI ﬁndings of
human glioma, which include obvious contrast enhance-
ment and a surrounding irregular inﬁltrative morphology
along the interface with the adjacent white matter [17–19].
Accordingly we characterized the MR imaging properties
of the hTSC and U87 models in vivo using conventional
MRI techniques. We applied these methods serially over
several weeks to chronicle the progression of glioma as
would be done during therapeutic agent development. The
results illustrate that the hTSC—MRI mouse model reca-
pitulates the MR ﬁndings diagnostic of human glioma and
is a suitable platform for preclinical testing of new thera-
peutic and imaging approaches.
Materials and methods
Mouse xenograft models
Animal subjects
SCID mice of either sex and weighing between 20 and 25 g
were housed in micro-isolator cages with autoclaved bed-
ding, and supplied with autoclaved food and water. Proper
procedures for SCID mouse handling, husbandry and
attention to comfort and clinical condition after tumor
implantation were strictly observed. The entire, detailed
study protocol was reviewed and approved by the institu-
tional review committee for animal research [Brigham and
Women’s Hospital (BWH) IACUC].
Cell lines
The U87 cell line was grown as an adherent culture in
media containing serum. Primary high grade human glioma
(glioblastoma) tissue was acquired surgically, dissociated,
and cultured in stem cell selection media to form
tumorspheres.
Patient derived glioma cells
The tumor tissue was freshly acquired during surgery
performed before the patient underwent any chemo- or
radiotherapy. The patient had a typically contrast enhanc-
ing mass upon MRI examination prior to surgery. Pathol-
ogy examination of the tissue conﬁrmed that the tumor was
a primary glioblastoma. Following acquisition the tumor
tissue was immediately dissociated in artiﬁcial CSF. The
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123glioblastoma cells were plated into dishes containing stem
cell isolation media and after 5 days the fully formed tu-
morspheres were dissociated and the cells implanted into
mice [8].
Intracranial implantation
Aseptic surgical methods were followed in accordance
with BWH guidelines. The U87 cultures and the tumor-
spheres (hTSC) were dissociated, counted, and concen-
trated into a compact suspension (1–2 ll). The mice were
anesthetized with ketamine/xylazine, the head was swab-
bed with Betadine
, and body temperature was maintained
with a circulating water pad. Tumor cell suspensions were
injected stereotaxically into the right frontal cortex at 1 ll/
min using a 5 ll Hamilton syringe [21]. The syringe was
left in place for 5 min before retraction to prevent reﬂux of
the injected material. One group of mice (n = 7) was
injected with approximately 1,500 hTSCs. A second group
(n = 6) was implanted with 10,000 U87 cells; a relatively
larger number of these cells was needed in order to
establish viable tumors which approximated the size of the
hTSC gliomas in a similar time frame.
Longitudinal imaging studies
Imaging schedule
MRI imaging of U87 and hTSC tumors was performed
every week in U87 mice starting at week 3 and every
2 weeks in hTSC mice starting at week 4. This was the
imaging schedule that we found best balanced tumor via-
bility with growth rates, which varied with tumor size at
various timepoints. The hTSC tumor was not detectable by
imaging until week 4 and it grew rapidly thereafter. The
growth rate between U87 tumors was relatively uniform
between subjects, and the mice were sacriﬁced after the
second scan (week 2), while the hTSC mice were imaged
between 2 and 5 times (weeks 2–5) before sacriﬁce,
reﬂecting the greater heterogeneity of hTSC tumors in
terms of growth rate.
MR imaging protocol
The mice were anesthetized with a mixture of 1.5% iso-
ﬂuorane and 95% oxygen throughout imaging. MRI was
performed on a 4.7T horizontal bore system interfaced with
a commercial scanner console (Bruker BioSpin Corpora-
tion, MA) using a homogenous quadrature birdcage head
coil. Coronal T2-weighted images (T2WI) (TR/
TEeff = 2,000/72 ms) were acquired with a 2D fast spin
echo sequence at 1 mm slice thickness with
80 lm 9 130 lm in-plane resolution. Magnevist
Tm Gd-
DTPA was injected intraperitoneally at 0.7 mmol/kg and
coronal T1-weighted images (T1WI) (TR/TEeff = 417/
24.5 ms) were acquired once before and twice after con-
trast injection. Post-contrast imaging was performed at
12 min after injection, which based on our prior experience
ensured optimal contrast enhancement (data not shown).
Data analysis
MR tumor morphology
A trained, blinded observer who was unaware of the origins
of each MR acquisition, evaluated the MR volumes in
terms of how well circumscribed the tumor boundary
appeared and in terms of the presence or absence of an
irregular inﬁltrative zone.
Fig. 1 MRI features of 2 week U87 and hTSC tumors. a U87 tumor
T2W acquisition. Note the smooth outline of the U87 tumor (arrow).
b Shows the post-contrast T1W image for the same tumor/slice as in
panel (a). The tumor can be seen to be clearly enhancing. c T2W
image slice of hTSC tumor. Note the irregular tumor outline (arrows),
invasion of ventricular areas, non uniform shading, and an invasive
proﬁle on the left of the main mass. The expanded view of the tumor
indicates the irregular and invasive nature of the hTSC tumor. d Post-
contrast T1W image slice for same tumor as in panel (c). The hTSC
tumor displays minimal contrast enhancement
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Histology was performed to conﬁrm the MR ﬁndings. The
mouse brains (n = 13: n = 6 U87, n = 7 hTSC) were
removed and sliced to 1 mm thickness, matching the MR
slice thickness. The 1 mm slices were ﬁxed in formalin,
sectioned to 5 lm, and stained with hematoxylin and eosin
(H&E). The H&E sections were examined by a pathologist,
and cellular atypia, anaplasia, mitotic activity, microvas-
cular proliferation, inﬁltration and tumor border topogra-
phy, and necrosis were observed, quantiﬁed and tabulated.
The tabulated data was then compared to the ﬁndings for
the corresponding MR slice acquisitions.
MR contrast enhancement measurements
Brain enhancement represents a measure of tumor micro-
vascular permeability, and relates to how therapeutic
agents might be distributed within a tumor and whether
contrast agents can highlight a small tumor. We used the
usual normalization method in which a ratio of contrast
enhancement is determined by comparing tumor tissue to
contralateral normal brain. We also calculated a ratio of
enhancement comparing the tumor with cervical skeletal
muscle (sternocleidomastoid). This was performed to pro-
vide a check for the tumor versus normal brain ratio, since
it is possible that inaccuracies might arise from altered
permeability in the reference white matter due to tumor
inﬁltration and edema.
The tumor to contralateral white matter ratio (TWR) and
the tumor-muscle enhancement ratio (TMR) were the mean
signal intensity of the enhanced tumor divided by mean
signal intensity of white matter and cervical muscle,
respectively, at the 12 min post-contrast T1WI. Maximum
enhanced regions of interest (ROI) were selected manually
on the pre- and post-contrast images by a blinded observer
who was not aware of the identities of the scans. The T1
and T2 acquisitions for each subject were cross-referenced
to ensure proper ROI location.
Results
Tumor morphology imaged by MRI
All the U87 tumors (n = 6) had a well-demarcated margin
(Fig. 1), and no central necrosis was observed. They had
relatively uniform hyperintensity compared to surrounding
brain parenchyma on T2WI, and all displayed clearly vis-
ible contrast enhancement that was quite uniform. Hydro-
cephalus often develops with U87 tumors in mice, and was
observed in four of the animals. However, no necrotic
regions were detected with the U87 tumors. In contrast the
hTSC tumors (n = 7) exhibited an irregular morphology,
and by 6 weeks all the T2WI images displayed variably
enhancement regions compared with the uniformity of
enhancement seen in U87 tumors. Intratumoral necrosis
was not evident on the early scans, but was clearly visible
Fig. 2 Histology of U87 and
hTSC tumors. All images H&E,
t tumor, b normal brain. a U87
tumor appears rounded (darker
staining regions) with distinct
boundaries. b U87 tumor image
clearly shows a typical rounded
and cleanly demarcated tumor
proﬁle. c Closer view of U87
tumor shows very little
inﬁltration of adjacent normal
brain. d Overview of hTSC
tumor showing highly scattered
and invasive tumor with
irregular outline (tumor includes
darker staining areas) e hTSC
tumor invasion into
subventricular zone along
ventricles. f hTSC tumor cell
inﬁltrate into brain with no clear
brain-tumor boundary
476 J Neurooncol (2011) 104:473–481
123in four mice between 6 and 10 weeks after hTSC implan-
tation. Hydrocephalus due to blockage of the brain ven-
tricles appeared in all hTSC animals by 8 weeks.
Histopathological correlation with MRI morphology
There was no signiﬁcant difference between U87 and hTSC
tumors in terms of cellular atypia, anaplasia, mitotic
activity, and microscopic necrosis. This suggests that fail-
ure to detect necrosis in the U87 tumors with MRI may
have been due to limitations in MR sensitivity. Notwith-
standing, the hTSC tumors were much more irregular that
U87 tumors in terms of their overall morphology (Fig. 2).
The hTSC tumors showed a very pronounced cellular
inﬁltration of normal brain parenchyma, and were aggres-
sively invasive. Subventricular zone inﬁltration was pres-
ent in 6 of 7 hTSC tumors, compared to 0 of 6 of the U87
tumors (Fig. 2a–c). The hTSC tumors very much mimicked
human glioma, exhibiting distinct, irregular masses of
growth with inﬁltrative components present to varying
degrees in different mice and at different time points.
TMR and TWR contrast enhancement
In the U87 tumors, which consistently contrast enhanced,
the ﬁnal mean TWR was 1.67 ± 0.23 with variance of
13.9, as represented by the maximally enhanced region
(Fig. 1). Mean TMR using the same tumor regions was
1.11 ± 0.06 with variance of 5.6. Both normalization
methods showed similar trends in terms of enhancement,
but the TWR was more variable, possibly due to the effects
of white matter edema or variations in blood brain barrier
permeability and contrast diffusion.
Contrast enhancement
The hTSC tumors did enhance in 11 of 18 time point
measurements (n = 7 mice), but a signiﬁcant proportion
showed very little or no enhancement at early times. The
range for enhancing regions was 8.5–233%. During the
development of the hTSC tumors, there was an increase of
TWR and TMR across all animals (n = 7). A representa-
tive example is shown in Fig. 3a showing an abrupt change
of vascular permeability. The permeability of all hTSC
tumors increased during the course of tumor development
and eventually did reach that of U87 tumors (Fig. 4a–c).
hTSC tumors exhibited greater variability in microvascular
permeability within tumors and across animals than did the
U87 tumor group.
MR detection of subtle microvascular effects
in hTSC tumors
Our data revealed that minimally enhancing hTSC tumor
did in fact show subtle evidence of increased microvascular
permeability during the beginning of 2-week period. Fig-
ure 5 shows the MRI characteristics of a representative
example from the minimally enhancing glioma. The tumor
was very large and had a long T2 (Fig. 5a), but relatively
modest enhancement on post-Gadolinium T1WI (Fig. 5b).
The invasive tumor tissue (T2WI, Fig. 5c) indicated by the
thin white arrows showed very mild enhancement in
Fig. 5d. Oval ROIs were drawn on the post-contrast T1WI
depicting the location of the cervical muscle reference sites
in Fig. 5d, guided by the T2W image of 5d. Interestingly,
even though the invasive tumor tissue was subtly enhanced,
Fig. 5d shows that on the corresponding post-contrast
T1WI, it was hypointense compared to muscle. In contrast
the representative MRI of a U87 tumor in Fig. 5g shows
that these tumors are highly enhancing compared to muscle
Fig. 3 Longitudinal imaging of hTSC tumors. Four weeks after
implantation the hTSC tumors were hyperintense on T2WI (a) and
showed post-contrast enhancement in T1WI (b). From the 4th week to
6th week post-inoculation, the tumor grew from 4.4 mm diameter (c–
d) to 6.8 mm diameter as shown in this T2WI (e–f). Even at 6 weeks
the tumor did not enhance as indicated by the post-contrast T1WI (d).
By the 8th week the tumor had enlarged signiﬁcantly as shown by the
T2WI acquisition (e), the mouse evinced signs of hydrocephalus, and
the post-contrast T1WI image was strongly enhanced
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123on the delayed post-Gadolinium T1WI. These data reveal
that microvascular permeability patterns and changes can
be expected to be quite different using the U87 model
versus the more physiologically relevant hTSC tumor
model.
Discussion
We report the MR imaging characteristics of a new human
stem cell (hTSC) xenograft model [9, 13, 15]. This model
was recently developed in response to the generally per-
ceived need for animal models that reproduce the
angiogenic and invasive natural history of human glioma
[1, 13, 15]. MR imaging is indispensable for managing
glioma patients, and MRI has been increasingly used for
the assessment of drug effects in animal models of brain
cancer [1, 17–19]. Therefore, we sought to complete the
hTSC model by characterizing its MR features relative to
well-established MR ﬁndings in human glioma, and to the
widely used U87 glioma model. Conventional MR exam-
inations validated histologically, revealed that hTSC
tumors mimicked the MR proﬁle typically observed with
glioma patients. The MRIs revealed evidence of angio-
genesis and/or increased tumor vessel permeability via
longitudinally developing, irregularly distributed contrast
enhancement, tumor invasiveness, and heterogeneity
Fig. 4 Contrast enhancement
over time in U87 versus hTSC
tumors. a MR image slices
acquired for a U87 tumor, at
two timepoints separated by
14 days. The upper panels
marked ‘start’ are the ﬁrst pair
of T2W and T1W post contrast
images. For the U87 tumor the
initial and ﬁnal ‘end’
acquisitions show the same
degree of strong enhancement,
even though they differ in size.
Note the smooth outline of the
tumor at 14 days. b MR images,
14 days apart, acquired for an
hTSC tumor. The initial
acquisition shows little or no
enhancement, while the 14 day
acquisition has strong
enhancement. Note the irregular
outline of the tumor in the
contrast enhanced image at the
second timepoint. c Quantitative
representation of contrast
enhancement for U87 tumors,
for hTSC tumors at beginning of
2-week period ‘start’ and at
conclusion of 2-week period
‘end’. The U87 contrast versus
hTSC at start of period differed
signiﬁcantly (P = 0.0001;
parametric, unpaired T-test),
and the start hTSC contrast
differed from that at the end
(P = 0.0002). The mean (line
x), the range (box) and the
standard deviation (bars) are
indicated for each group
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123within and between tumors. As expected, the well cir-
cumscribed, spherical U87 MR proﬁle and uniform con-
trast enhancement did not resemble the MR appearance of
patient gliomas.
Previous investigations of quantitative permeability
imaging in various tumor models has established that
tumor enhancement is produced by a combination of: (1)
increase in capillary blood volume due to an increase in
blood ﬂow within existing brain capillaries, (2) impairment
of the blood–brain barrier (BBB) in native capillaries due
to diffusible paracrine factors released by the tumor or host
immune response, and (3) the formation of new leaky
tumor microvessels (angiogenesis), which is the main
effect [24, 25]. Thus while Gd detection represents an
admixture of effects, escalating Gd enhancement over time
is one of the best established clinical surrogate imaging
markers of angiogenesis [24, 25]. Low grade human glio-
mas initially show little contrast enhancement, and then as
they progress to higher grade tumors they begin to express
strong contrast enhancement [26–30]. On the other hand,
high grade gliomas, viz., the glioblastomas, exhibit vivid
contrast enhancement upon ﬁrst presentation, but this is not
always the case, as some glioblastomas do not or mini-
mally enhance initially [31, 32]. Moreover patients are MR
imaged after they are symptomatic, so it is possible that
early tumors, if they were to be MR imaged, might not
enhance until they have progressed sufﬁciently to cause
symptoms. In any case the ﬁnding that not all the hTSC
tumors enhanced initially, that they all enhanced at
2 weeks, and that they exhibited a heterogeneous and
irregular morphology suggests that this model mimics the
human disease reasonably well.
Since the hTSC mouse model exhibits a progression
from minimal enhancement to full enhancement, it may
be an attractive translational test platform for the appli-
cation of advanced imaging methods to deﬁne the tem-
poral evolution of abnormal permeability in inﬁltrative
progressive glioma. The dynamics and kinetics of tumor
and brain delivery of therapeutic and contrast agents is
considerably inﬂuenced by variations in vascular perme-
ability, and based on our results the U87 and hTSC
tumors can be expected to behave differently from each
Fig. 5 MR detection of subtle microvascular effects in hTSC tumors.
a T2W image of a large hTSC tumor. b Post-contrast T1W image of
the same slice; tumor was very large but the contrast enhancement
and thus vascular permeability were relatively low. c T2W image
used to deﬁne cervical muscle ROIs and tumor invasion (thin arrows;
thick arrow shows normal tissue). d invasive tumor tissue showing
only mild enhancement. Even though the invasive tissue showed
subtle enhancement, it was hypointense compared with the cervical
muscle reference loci. e T2W image of cervical muscle in a U87
tumor bearing mouse. This image was used to deﬁne reference ROIs.
f Is the T1W post-contrast image of the same slice as the cervical ROI
T2W image and shows enhancement in the muscle tissue. g Shows the
post-contrast T1W image of the U87 tumor which is clearly
hyperintense compared to the cervical muscle and surrounding brain
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123other in this regard over at least the ﬁrst few weeks after
implantation.
A limitation of the hTSC model is that it involves the
implantation of human glioma cells into an athymic nu/nu
or SCID mice. These murine models are immunocompro-
mised, and it has been demonstrated that T cells do occur
within gliomas and contribute to their natural history [33].
The abrupt transformation from low enhancement to
high enhancement in only the hTSC model, documents the
sensitivity range of MRI in this model. This event is
thought to result from the release of angiogenic factors and
matrix metalloproteinases, and in humans heralds the onset
of an angiogenic, aggressive glioma phenotype [8, 28, 30].
Future work on this topic will require a comprehensive
study in which the tumors are staged, and vascular per-
meability and density around the tumor are characterized
using MR functional and histological approaches. This is
beyond the scope of the present study, but a further sys-
tematic examination of the possible relationship between
suddenly increased MR contrast enhancement in hTSC
tumors and the angiogenesis will be the subject of a future
research.
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